Why Is Humacyte Stock Falling Thursday? - Humacyte (NASDAQ:HUMA)

Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a dilutive $50M share offering.

Raccontata dabenzinga.com